Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 56

Sort by

Sort Order Select

Journal Articles

Safety analysis of axatilimab in patients with chronic graft-versus-host disease in an expanded access program

Leyla Shune, Anthony Stein, Damiano Rondelli, Laurie Davis, Shalini Shenoy, Britnie Thomas, Emily Andersen, Elizabeth Jordan, Karim Moftah, Zhenyi Xue, Hannah Choe

Blood (2025) 146 (Supplement 1): 6008.

https://doi.org/10.1182/blood-2025-6008

Published: 2025

Journal Articles

Longterm survival and late effects following hematopoietic cell transplantation for sickle cell disease into a modern era: A center for international blood and marrow transplant research (CIBMTR) analysis

Elizabeth Stenger, Ruta Brazauskas, Andrew Peterson, Stephanie Bo-Subait, Minoo Battiwalla, David Buchbinder, Betty K. Hamilton, Bipin Savani, Helene Schoemans, Michelle Schoettler, Mohamed Sorror, Rachel Phelan, Shalini Shenoy, Lakshmanan Krishnamurti

Blood (2025) 146 (Supplement 1): 1051.

https://doi.org/10.1182/blood-2025-1051

Published: 2025

Journal Articles

High event-free (EFS) and overall survival (OS) after non-total body irradiation (TBI) conditioning and allogeneic hematopoietic cell transplantation (HCT) in next-generation-sequencing minimal residual disease (NGS-MRD) negative B-acute lymphoblastic leukemia (B-ALL): Results from the EndRAD trial (PTCTC ONC1701)

Blood (2025) 146 (Supplement 1): 163.

https://doi.org/10.1182/blood-2025-163

Published: 2025

Journal Articles

Distinct Biological Subtypes of Chronic GVHD after Pediatric Hematopoietic Cell Transplantation

Blood blood.2025028625.

https://doi.org/10.1182/blood.2025028625

Published: 2025

Includes: Supplemental data

Journal Articles

Five-Year Outcomes of the “Abatacept Combined with a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease (GVHD) Prophylaxis: A Randomized Controlled Trial” (‘ABA2‘)

Blood (2024) 144 (Supplement 1): 3516.

https://doi.org/10.1182/blood-2024-205130

Published: 2024

Journal Articles

Alemtuzumab, Fludarabine, Melphalan, and Thiotepa As Reduced-Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in Inborn Errors of Immunity

Thomas Pfeiffer, Stephanie Hyde, Shalini Shenoy, Melissa Mavers, Robert J. Hayashi, Feng Gao, Lisa Madden, Troy Quigg, Michael J. Eckrich, Sima Bhatt, Jeffrey J. Bednarski

Blood (2024) 144 (Supplement 1): 375.

https://doi.org/10.1182/blood-2024-194650

Published: 2024

Journal Articles

Successful Allogenic Stem Cell Transplantation Using Radiation-Free Reduced Intensity Conditioning in Idiopathic Pediatric Severe Aplastic Anemia - a Single Center Experience

Mithra Lakshmi Narasimhan, Irem Eldem, David B Wilson, Ginny Schulz, Robert J Hayashi, Shalini Shenoy

Blood (2024) 144 (Supplement 1): 2110.

https://doi.org/10.1182/blood-2024-206543

Published: 2024

Journal Articles

Fertility and Sexual Development Outcomes in Pubertal and Post-Pubertal Children and Young Adults after Myeloablative Conditioning (MAC) and Familial Haploidentical T-Cell Depleted Allogeneic Stem Cell Transplantation

Hanif Mouehla, Maya Siegel, Edo Schaefer, Julie-An Talano, Shalini Shenoy, Theodore B. Moore, Jordan Milner, Christine Duncan, Anne Panarella, Lauren Harrison, Erin Morris, Mitchell S. Cairo

Blood (2024) 144 (Supplement 1): 7393.

https://doi.org/10.1182/blood-2024-208814

Published: 2024

Journal Articles

Reduced Intensity Haploidentical Bone Marrow Transplantation in Adults with Severe Sickle Cell Disease: BMT CTN 1507

Blood (2023) 142 (Supplement 2): LBA-4.

https://doi.org/10.1182/blood-2023-192022

Published: 2023

Journal Articles

Treatment of Refractory Adenovirus (ADV) Infections Using Adv-Specific Cytotoxic T-Lymphocytes (CTLs) in Children, Adolescents and Young Adults (CAYA) Post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), Solid Organ Transplantation (SOT), or with Primary Immunodeficiency (PID)

Blood (2023) 142 (Supplement 1): 4836.

https://doi.org/10.1182/blood-2023-188013

Published: 2023

Journal Articles

Abatacept-Prophylaxis Based Haploidentical Transplantation May Allow Sustained Engraftment and Offset Gvhd in Non-Malignant Disorders

Alexander I. Ngwube, Niketa C. Shah, Ginny Schulz, Lakshmanan Krishnamurti, Shalini Shenoy

Blood (2023) 142 (Supplement 1): 4901.

https://doi.org/10.1182/blood-2023-191145

Published: 2023

Journal Articles

Regimen Intensity and Age Affect Transplant-Related Outcomes after Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Registry Study

Blood (2023) 142 (Supplement 1): 4904.

https://doi.org/10.1182/blood-2023-182532

Published: 2023

Journal Articles

Donor Hemoglobin Genotype Does Not Impact Outcomes Following Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Study

Elizabeth Stenger, Tami D. John, Deepak Chellapandian, Rikin Shah, Scott Gillespie, Yijin Xiang, Katie Liu, Monica Bhatia, Gregory M.T. Guilcher, Jennifer Jaroscak, Kimberly A. Kasow, Jennifer Krajewski, Alexander I. Ngwube, Hemalatha G. Rangarajan, John T. Horan, Lakshmanan Krishnamurti, Shalini Shenoy, Allistair Abraham

Blood (2023) 142 (Supplement 1): 4955.

https://doi.org/10.1182/blood-2023-188514

Published: 2023

Journal Articles

Outcomes after RIC and Abatacept-Based Acute and Chronic Gvhd Prophylaxis in Allogeneic Transplantation for Sickle Cell Disease - Can Calcineurin Inhibitor Use be Curtailed?

Niketa C. Shah, Alexander I. Ngwube, David A Jacobsohn, Shalini Shenoy

Blood (2023) 142 (Supplement 1): 2185.

https://doi.org/10.1182/blood-2023-190524

Published: 2023

Journal Articles

Higher abatacept exposure after transplant decreases acute GVHD risk without increasing adverse events

Blood (2023) 142 (8): 700–710.

https://doi.org/10.1182/blood.2023020035

Published: 2023

Includes: Supplemental data

Journal Articles

Normalization of cerebral hemodynamics after hematopoietic stem cell transplant in children with sickle cell disease

Monica L. Hulbert, Melanie E. Fields, Kristin P. Guilliams, Priyesha Bijlani, Shalini Shenoy, Slim Fellah, Alison S. Towerman, Michael M. Binkley, Robert C. McKinstry, Joshua S. Shimony, Yasheng Chen, Cihat Eldeniz, Dustin K. Ragan, Katie Vo, Hongyu An, Jin-Moo Lee, Andria L. Ford

Blood (2023) 141 (4): 335–344.

https://doi.org/10.1182/blood.2022016618

Published: 2023

Includes: Supplemental data

Journal Articles

The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with KMT2A -Rearranged or NPM1 Mutant AML: Updated Results of a Phase (Ph) 1 Study

Blood (2022) 140 (Supplement 1): 150–152.

https://doi.org/10.1182/blood-2022-164849

Published: 2022

Journal Articles

Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplant for Hyperinflammatory Inborn Errors of Immunity

Rebecca A. Marsh, Soyoung Kim, Kyle Hebert, Christopher C. Dvorak, MD, Victor Aquino, MD, K. Scott Scott Baker, MD MS, Deepak Chellapandian, MD, Blachy Davila, MD, Christine Duncan, MD, Michael J. Eckrich, MD MPH, George E. Georges, MD, Timothy S. Olson, MD PhD, Michael A Pulsipher, MD, Shalini Shenoy, MD, Elizabeth Stenger, MD, Mark Vander Lugt, MD, Lolie C. Yu, MD, Andrew Gennery, MD, Mary Eapen, MBBS, MS

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-139930

Published: 2020

Journal Articles

Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated Following Allogeneic Transplantation in Patients with Sickle Cell Disease

Niketa C. Shah, MD, Sweta Bhoopatiraju, Allistair Abraham, MD, Eric Jon Anderson, MD, Martin Andreansky, MD, Monica Bhatia, MD, Sonali Chaudhury, MD, Geoff D.E. Cuvelier, MD, Kamar Godder, MD MPH, Michael Grimley, MD, Gregory Hale, MD, Naynesh Kamani, David Jacobsohn, MD, Alexander I. Ngwube, MD, Jodi L. Skiles, MD, Lolie C. Yu, MD, Shalini Shenoy, MD

Blood (2020) 136 (Supplement 1): 33.

https://doi.org/10.1182/blood-2020-142696

Published: 2020

Journal Articles

Characterization of Peripheral Blood Mononuclear Cells Addback Following CD34 Enrichment, Engraftment and T and NK Cells Immune Reconstitution in Patients with High Risk Sickle Cell Disease (SCD) (IND 14359)

Yaya Chu, PhD, Julie-An Talano, MD, Lee Ann Baxter-Lowe, PhD, Carolyn A. Keever-Taylor, PhD, Erin Morris, RN, BSN, Harshini Mahanti, BS, MSCR, Janet Ayello, MS, MT(ASCP), Bryon Johnson, PhD, Rona Singer Weinberg, PhD, Qiuhu Shi, PhD, Theodore B. Moore, MD, Sandra Fabricatore, RN, PNP, MSN, Brenda J. Grossman, MD, Carmella van de Ven, MA, Shalini Shenoy, MD, Mitchell S Cairo, MD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-140425

Published: 2020

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Safety analysis of axatilimab in patients with chronic graft-versus-host disease in an expanded access program

Longterm survival and late effects following hematopoietic cell transplantation for sickle cell disease into a modern era: A center for international blood and marrow transplant research (CIBMTR) analysis

Distinct Biological Subtypes of Chronic GVHD after Pediatric Hematopoietic Cell Transplantation

Five-Year Outcomes of the “Abatacept Combined with a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease (GVHD) Prophylaxis: A Randomized Controlled Trial” (‘ABA2‘)

Alemtuzumab, Fludarabine, Melphalan, and Thiotepa As Reduced-Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in Inborn Errors of Immunity

Successful Allogenic Stem Cell Transplantation Using Radiation-Free Reduced Intensity Conditioning in Idiopathic Pediatric Severe Aplastic Anemia - a Single Center Experience

Fertility and Sexual Development Outcomes in Pubertal and Post-Pubertal Children and Young Adults after Myeloablative Conditioning (MAC) and Familial Haploidentical T-Cell Depleted Allogeneic Stem Cell Transplantation

Reduced Intensity Haploidentical Bone Marrow Transplantation in Adults with Severe Sickle Cell Disease: BMT CTN 1507

Treatment of Refractory Adenovirus (ADV) Infections Using Adv-Specific Cytotoxic T-Lymphocytes (CTLs) in Children, Adolescents and Young Adults (CAYA) Post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), Solid Organ Transplantation (SOT), or with Primary Immunodeficiency (PID)

Abatacept-Prophylaxis Based Haploidentical Transplantation May Allow Sustained Engraftment and Offset Gvhd in Non-Malignant Disorders

Regimen Intensity and Age Affect Transplant-Related Outcomes after Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Registry Study

Donor Hemoglobin Genotype Does Not Impact Outcomes Following Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Study

Outcomes after RIC and Abatacept-Based Acute and Chronic Gvhd Prophylaxis in Allogeneic Transplantation for Sickle Cell Disease - Can Calcineurin Inhibitor Use be Curtailed?

Higher abatacept exposure after transplant decreases acute GVHD risk without increasing adverse events

Normalization of cerebral hemodynamics after hematopoietic stem cell transplant in children with sickle cell disease

The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with KMT2A -Rearranged or NPM1 Mutant AML: Updated Results of a Phase (Ph) 1 Study

Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplant for Hyperinflammatory Inborn Errors of Immunity

Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated Following Allogeneic Transplantation in Patients with Sickle Cell Disease

Characterization of Peripheral Blood Mononuclear Cells Addback Following CD34 Enrichment, Engraftment and T and NK Cells Immune Reconstitution in Patients with High Risk Sickle Cell Disease (SCD) (IND 14359)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only